Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

This study discusses the use of oral contraceptives as a treatment for hyperandrogenism, showing improvement in hirsutism and acne for many women and possibly providing metabolic benefits with certain formulations.

In this study, DHT was found to inhibit hair growth in mice by decreasing IGF-I production in dermal papillae through reduced sensory neuron stimulation.

This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.

This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.

This study found that HBV infection altered steroid metabolism in male mice, significantly increasing levels of dehydroepiandrosterone and reducing dihydrotestosterone, which may suppress viral replication by affecting HBV promoter activity.

This review discusses symptom-driven treatment approaches for PCOS, focusing on ovulation induction, androgen reduction, and weight management, and reports recent advances like recombinant FSH and GnRH-agonist protocols without providing new clinical results.

This review discusses the management of androgenic disorders in women, highlighting that treatment is generally more effective than recognized, though improvement may take weeks or months to appear.

This review explores the evaluation and treatment of hirsutism, emphasizing a systematic approach to uncovering its causes and recommending combination therapies for effective management, but presents no new results.

This narrative review discusses the ongoing concerns about the adverse effects of finasteride in treating androgenetic alopecia, which some reports indicate may be irreversible even after stopping the drug, but it does not report new clinical results.

This review explores various therapeutic options for managing female hirsutism, emphasizing the effectiveness of low-dose finasteride and cyproterone acetate, but it presents no new clinical results.

This report describes two cases of postmenopausal hyperandrogenism where GnRH analogue use suggested an ovarian source of excess androgens, leading to a diagnosis of benign ovarian tumors.

Different substances affect hair and skin cell growth in various ways.

Different substances affect hair and skin cell growth in various ways, with some promoting and others inhibiting cell proliferation.

In this study, manipulation of the enzyme 5α-reductase type 2 in human hepatocytes altered lipogenesis, suggesting clinical implications for patients using 5α-reductase inhibitors by affecting glucocorticoid action on hepatic lipid metabolism.

In this case report, a transgender woman experienced scalp hair regrowth after approximately six months of oral estradiol and spironolactone treatment, achieving testosterone levels within the normal female range.

This case study identified a probable pure testosterone-secreting ovarian tumor in a woman with increased facial hair and elevated testosterone levels, confirmed by histological examination as Leydig cells hyperplasia, which normalized testosterone and symptoms post-surgery.

In this study, the safety of finasteride in rats varied depending on dosing time, while its effectiveness on prostate weight reduction remained consistent.

The authors concluded that plasma levels of 3α-diolG, ADTG, and DHTG in women with hyperandrogenic disorders primarily reflect adrenal androgen contributions rather than peripheral action, suggesting a potential index for treatment effectiveness.

This study found that the DKK3-CKAP4 signaling axis is involved in fibroimmune remodeling in androgenetic alopecia and that targeting this pathway may restore a regenerative hair follicle environment, offering a potential therapeutic strategy to counteract hair follicle miniaturization.

This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.

This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.

This study reports that spironolactone has shown effectiveness in improving hair density and reducing shedding in female pattern hair loss, particularly for women with hyperandrogenism, though benefits often diminish after stopping treatment.

This article discusses psychological and clinical responses to the recent pandemic and emphasizes the potential for a virus-free future, but it reports no new research findings.

Use finasteride over dutasteride for hair loss; consider topical treatments and weigh risks.

This study established a method to create stem cell-derived dermal papilla cells and found that their conditioned medium significantly boosts hair growth and offers anti-inflammatory benefits in mice, surpassing minoxidil and addressing androgen-related hair loss.

This review discusses various aspects of polycystic ovary syndrome, including its prevalence, diagnosis, and treatment options, and reports no new empirical results.

This study found that treatment with oral contraceptives containing 35mg ethinylestradiol and 2mg cyproterone acetate significantly reduced serum AMH levels in women with clomiphene citrate-resistant polycystic ovary syndrome, unlike metformin.

This article discusses the use of oral contraceptives for treating hyperandrogenism in women, reporting improvement in most patients, especially in reducing new hair growth, but presents no new clinical findings.